Gold prices dip as December rate cut bets wane; economic data in focus
Structure Therapeutics Inc ADR has reached a new 52-week high, with its stock price hitting 37.66 USD. This milestone reflects a significant upward trend, as the company’s stock has experienced a 17.64% increase over the past year. The biopharmaceutical company, which focuses on developing novel therapies, has seen its stock price steadily climb, culminating in this new high. Investors are taking note of Structure Therapeutics’ growth trajectory, as the company continues to advance its pipeline and expand its market presence. According to InvestingPro, analyst consensus remains strongly bullish with price targets ranging from $44 to $120, suggesting significant potential upside despite the stock currently trading slightly above its Fair Value. For deeper insights, including 12 additional ProTips and comprehensive analysis, check out the Pro Research Report available for Structure Therapeutics—one of 1,400+ US equities covered with expert analysis on the platform.
In other recent news, Structure Therapeutics has garnered attention from multiple analyst firms ahead of critical trial readouts. BMO Capital has reiterated an Outperform rating with a $100.00 price target, emphasizing the importance of the upcoming Phase 2b trial results for aleniglipron in obesity. Piper Sandler also reiterated an Overweight rating with a $93.00 price target, suggesting that the results could validate the company’s lead drug candidate. H.C. Wainwright maintained a Buy rating and a $60.00 price target, highlighting the company’s position in the oral weight loss drug market with promising early results.
Meanwhile, Jazz Pharmaceuticals announced the appointment of Ted W. Love, M.D., to its Board of Directors, effective December 1, 2025, as Kenneth O’Keefe plans to retire. Dr. Love brings extensive experience from his previous roles, including President and CEO of Global Blood Therapeutics.
Additionally, Terns Pharmaceuticals maintained its Market Outperform rating from Citizens, with a $20.00 price target. The company is positioning its oral GLP-1 asset as differentiated on safety and plans to seek partnerships following data release. These developments reflect ongoing strategic and operational activities within these companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.